Basel, Switzerland
Basel, Switzerland

Time filter

Source Type

News Article | February 20, 2017
Site: phys.org

Researchers at The University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) have designed a virus-like nanoparticle (VNP) that delivers drugs directly to the cells where they are needed. The lead author of a paper on the topic, Dr Frank Sainsbury, said the VNP was made from the structural proteins that formed the virus's protective shell. "Viruses have evolved to contain and protect bioactive molecules," Dr Sainsbury said. "They've also evolved smart ways to get into cells and deliver these bioactive molecules. "The VNP is an empty shell. It looks like a virus but it's not infectious. This makes it safe to use as a targeted drug delivery system." With infectious viral genes removed, empty shells can be loaded with small molecules or proteins resulting in a stable, well-protected therapeutic package. The outside of the shell then determines where the package will go. The ability to send drugs directly to their target is a critical goal in the development of safe, effective therapeutics. Currently many drugs, including anti-cancer chemotherapies, must be administered at high doses in order to have a therapeutic effect. This can lead to harsh side effects because drugs can damage healthy cells as well as intended targets. Dr Sainsbury and his colleagues developed a VNP using the Bluetongue virus, which normally infects cows, sheep and other ruminants. They picked the virus because of its stable shell, made of hundreds of proteins that are known to bind to a molecule found in high levels around many cancer cells. Dr Sainsbury teamed up with Dr Michael Landsberg at UQ's School of Chemistry and Molecular Biosciences and researchers at the Institute for Molecular Bioscience and the UK's John Innes Centre. They were able to demonstrate that the porous VNPs could be filled with small molecules for drug delivery and it also was possible to design VNPs to contain larger molecules, such as therapeutic proteins. Importantly, the researchers showed VNPs were able to bind to breast cancer cells, and then be absorbed. Dr Sainsbury said the next step was to load the VNPs with anti-cancer drugs and see if they could kill cancer cells without harming healthy cells. Although VNPs are highly complex and difficult to synthesise, Dr Sainsbury said they could be easily produced in the leaves of Nicotiana benthamiana, a wild relative of tobacco. By providing plant cells with genetic instructions for making VNPs, the plant was able to assemble virus protein shells without any permanent change to the plant's own genetic code. Dr Sainsbury said one day greenhouses may be able to produce large amounts of the nanoparticles within days. "This research unlocks a myriad of potential applications in therapeutic delivery," Dr Sainsbury said. Because the nanoparticles they have designed are highly stable, the AIBN research team is exploring other biotechnology applications. Explore further: Plant-made virus shells could deliver drugs directly to cancer cells


PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced that the National Institutes of Health Blueprint Neurotherapeutics Network has awarded the company a grant under the Small Business Innovation Research (SBIR) program to advance novel treatments for epilepsy. Terms of the grant provide the potential for up to $2.5 million of direct support based on milestone attainment. The award supports Knopp’s preclinical and clinical development of small-molecule drug candidates directed to a validated, anti-seizure pharmaceutical target known as Kv7.2. Knopp expects initially to advance novel Kv7 activators in neonatal epileptic encephalopathy associated with a rare mutation in the KCNQ2 gene. These mutations cause severe epilepsy and profound developmental disability in newborns and infants, for whom conventional anti-seizure medications are insufficient or ineffective. Steven Dworetzky, PhD., Knopp’s Chief Scientific Officer and the Principal Investigator in the Blueprint-funded project, is a longtime Kv7 researcher whose group first cloned the Kv7.2 gene during his former tenure with the Bristol-Myers Squibb Co. “ This award comes not just with significant direct support but with access to top collaborators in the Blueprint Neurotherapeutics Network, who are committed to the discovery of disease-modifying treatments for the underlying causes of epilepsy,” he said. “ We already see evidence that our Blueprint collaboration will accelerate our move into human studies in challenging indications, including KCNQ2 encephalopathy and treatment-resistant, generalized epilepsy syndromes.” Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need in clearly defined patient populations. Our clinical-stage small molecule, dexpramipexole, will be entering Phase 2/3 clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. For more information, see www.knoppbio.com. Knopp’s Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH. This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.


News Article | February 22, 2017
Site: www.businesswire.com

DES MOINES, Iowa & DAVIS, Calif.--(BUSINESS WIRE)--Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd., NASDAQ: SEED), an agricultural biotechnology trait and seed provider, and Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a California-based company that develops and commercializes agricultural productivity traits and nutritional products, today announced their collaboration to achieve the first-ever export of a key corn biotechnology product developed in China to the United States for completion of global regulatory trials. The successful movement of this corn seed, containing an insect resistance/herbicide tolerance trait discovered and developed in China, to the Arcadia greenhouse represents a key milestone in Origin’s strategic business plan to achieve global regulatory approvals for cultivation and international grain movement. “ This first-of-its-kind export validates Origin’s leading position in China biotech and its close alignment with Chinese ministries leading the transformation of the domestic seed industry. Combining Origin’s robust pipeline of value-added Chinese traits and elite corn germplasm with Arcadia’s research and development infrastructure demonstrates our plan to capture a sizeable piece of China’s estimated billion-dollar corn seed trait market,” said Bill Niebur, Origin chief executive officer. “ As a leader in agtech focused on modernizing the traditional corn seed market, our international team remains focused on accelerating research and development to improve the lives of Chinese farmers.” Arcadia and Origin signed an agreement under which Arcadia will assist Origin in developing information for submission to regulatory authorities in the U.S., China and other countries for the approval of their traits in corn. This project involves production of inbred and hybrid seed lines under quarantine conditions in Arcadia greenhouses. “ Arcadia has the proven expertise to bring traits through the regulatory process successfully and efficiently,” said Raj Ketkar, Arcadia’s president and CEO. “ We have conducted hundreds of studies in the laboratory, greenhouse and field to gain regulatory approvals for various traits in major crops, and we have a strong regulatory team that has developed complete regulatory dossiers in multiple countries. This collaboration with Origin is an example of how our partners can leverage these capabilities to accelerate the commercialization of novel ag biotech traits.” “ Ultimately, this milestone achievement will create more choices and opportunities for farmers,” said Jihong Liang, Origin chief technology officer. “ This is an important achievement, showcasing Origin’s competitive advantage in science and global reach through collaborations inside China and beyond its borders. Origin is leading the way in gaining regulatory approvals for this critical advanced technology globally to drive future business growth.” Origin’s investment and focus aligns tightly with China’s 13th Five Year Plan, which calls for the modernization of agriculture as the foundation for building a prosperous society. The Chinese government, including the Ministry of Agriculture (MOA) and Chinese Academy of Agricultural Sciences (CAAS), has advanced a policy vision to facilitate seed industry innovation, improve the competitiveness of the Chinese ag tech industry and cultivate new seed varieties for farmers around the world. Through these actions, China has shown strong commitment to advancing its ag industry through new advances in biotechnology. Origin anticipates China commercialization of corn biotechnology at the end of this decade. Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please visit the Company’s website at: http://www.originseed.com.cn or http://www.originseed.com.cn/en/. Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia’s agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit www.arcadiabio.com. This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause the company’s actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company's intellectual property rights; and successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.


News Article | February 22, 2017
Site: en.prnasia.com

Insect resistant corn seed trait targeted at an estimated $1 billion marketDES MOINES, Iowa, Feb. 22, 2017 /PRNewswire/ -- Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech Ltd.) (NASDAQ: SEED), an agricultural biotechnology trait and seed provider, and Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a California-based company that develops and commercializes agricultural productivity traits and nutritional products, today announced their collaboration to achieve the first-ever export of a key corn biotechnology product developed in China to the United States for completion of global regulatory trials. The successful movement of this corn seed, containing an insect resistance/herbicide tolerance trait discovered and developed in China, to the Arcadia greenhouse represents a key milestone in Origin's strategic business plan to achieve global regulatory approvals for cultivation and international grain movement. "This first-of-its-kind export validates Origin's leading position in China biotech and its close alignment with Chinese ministries leading the transformation of the domestic seed industry. Combining Origin's robust pipeline of value-added Chinese traits and elite corn germplasm with Arcadia's research and development infrastructure demonstrates our plan to capture a sizeable piece of China's estimated billion-dollar corn seed trait market," said Bill Niebur, Origin chief executive officer. "As a leader in agtech focused on modernizing the traditional corn seed market, our international team remains focused on accelerating research and development to improve the lives of Chinese farmers." Arcadia and Origin signed an agreement under which Arcadia will assist Origin in developing information for submission to regulatory authorities in the U.S., China and other countries for the approval of their traits in corn. This project involves production of inbred and hybrid seed lines under quarantine conditions in Arcadia greenhouses. "Arcadia has the proven expertise to bring traits through the regulatory process successfully and efficiently," said Raj Ketkar, Arcadia's president and CEO. "We have conducted hundreds of studies in the laboratory, greenhouse and field to gain regulatory approvals for various traits in major crops, and we have a strong regulatory team that has developed complete regulatory dossiers in multiple countries. This collaboration with Origin is an example of how our partners can leverage these capabilities to accelerate the commercialization of novel ag biotech traits." "Ultimately, this milestone achievement will create more choices and opportunities for farmers," said Jihong Liang, Origin chief technology officer. "This is an important achievement, showcasing Origin's competitive advantage in science and global reach through collaborations inside China and beyond its borders. Origin is leading the way in gaining regulatory approvals for this critical advanced technology globally to drive future business growth." Origin's investment and focus aligns tightly with China's 13th Five Year Plan, which calls for the modernization of agriculture as the foundation for building a prosperous society. The Chinese government, including the Ministry of Agriculture (MOA) and Chinese Academy of Agricultural Sciences (CAAS), has advanced a policy vision to facilitate seed industry innovation, improve the competitiveness of the Chinese ag tech industry and cultivate new seed varieties for farmers around the world. Through these actions, China has shown strong commitment to advancing its ag industry through new advances in biotechnology. Origin anticipates China commercialization of corn biotechnology at the end of this decade. Origin Agritech Limited, founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, is China's leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of crop seed biotechnologies, Origin Agritech's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Origin operates production centers, processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please visit the Company's website at: http://www.originseed.com.cn or http://www.originseed.com.cn/en/. Based in Davis, Calif., Arcadia Biosciences (Nasdaq: RKDA) develops agricultural products that create added value for farmers while benefitting the environment and enhancing human health. Arcadia's agronomic performance traits, including Nitrogen Use Efficiency, Water Use Efficiency, Salinity Tolerance, Heat Tolerance and Herbicide Tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia's nutrition traits and products are aimed at creating healthier ingredients and whole foods with lower production costs. For more information, visit www.arcadiabio.com. This communication contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting products based on biotechnology and, in general, for products for the agriculture industry; outcome of significant litigation and environmental matters, including realization of associated indemnification assets, if any; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns which could affect demand as well as availability of products for the agriculture industry; ability to protect and enforce the company's intellectual property rights; and successful integration of acquired businesses and separation of underperforming or non-strategic assets or businesses. The company undertakes no duty to publicly revise or update any forward-looking statements as a result of future developments, or new information or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/origin-arcadia-announce-china-biotechnology-collaboration-in-corn-300411337.html


News Article | February 15, 2017
Site: cen.acs.org

University of California, Berkeley, scientists have found entirely new classes of Cas proteins, the enzymes responsible for snipping DNA in the CRISPR gene-editing system. The discovery expands the ever-growing CRISPR toolbox and creates a new wrinkle in the ongoing patent dispute between Berkeley and the Broad Institute of Harvard University and MIT over the gene-editing technology. Jillian F. Banfield led the Berkeley team, which scoured 155 million genes from microbes that cannot be grown in labs to find the Cas proteins. These microbes live in places as varied as groundwater, acidic drainage from mines, and the intestines of infants. In addition to finding new versions of traditional Cas9 proteins, the researchers discovered entirely new classes of Cas enzymes, dubbed CasX and CasY (Nature 2016, DOI: 10.1038/nature21059). Because Cas proteins are large, it’s challenging to deliver them into cells for gene-editing purposes. The newly discovered CasX enzymes, however, are among the smallest Cas proteins known, potentially a key advantage over other Cas variants, including the Cas9 class of protein that’s used by almost everyone working with CRISPR today. Cas9 is part of microbial immune systems found in the pathogenic Streptococcus pyogenes and many other species. “There is just an incredible diversity of microbial life out there,” Banfield says. And the CasX and CasY discovery “is a beautiful example of the kinds of valuable things that can be found.” Banfield partnered with Jennifer A. Doudna’s lab at UC Berkeley to demonstrate CasX and CasY’s potential for gene-editing in bacterial cells. Doudna, a cocreator of the CRISPR/Cas tool along with Max Planck Institute for Infection Biology’s Emmanuelle M. Charpentier, is currently embroiled in a patent dispute with the Broad Institute over who holds the licenses to CRISPR systems that use Cas9. The Berkeley researchers recently filed a patent application related to the newly reported CasX and CasY enzymes. Because these variants are different enough from Cas9, they could give Doudna and colleagues a cushion if they lose the ongoing patent fight. The timing of the Berkeley team’s Nature report on CasX and CasY is impeccable. The week before it was published, several companies, including CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences—which are all tied to either Doudna or Charpentier—formalized an alliance to share, protect, and enforce their intellectual property. The Broad-associated Editas Medicine quickly retaliated and announced its own agreement with five universities, licensing “advanced forms of Cas9,” as well as a previously reported Cas9 alternative enzyme named Cpf1. Jacob S. Sherkow of New York Law School says that in retrospect, knowledge of CasX and CasY likely fueled the cross-licensing agreements. “That is the piece of the jigsaw puzzle we were missing” when the deals took place, Sherkow says. “It cannot be coincidence.” “It is possible that all of the companies involved in CRISPR technologies could avoid being ‘losers’ in the patent dispute by just using different versions” of Cas proteins, says Knut J. Egelie of the Norwegian University of Science & Technology. Alternatives to Cas9 “will level out the game and make the patent interference decision less important,” he adds. Banfield says her lab will continue exploring the mysterious genomes of difficult-to-cultivate microbes, while Doudna’s group will carry out gene-editing tests with the new enzymes in cells beyond bacteria. This article has been translated into Spanish by Divulgame.org and can be found here.


Sarasota, FL, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Anti-Microbial Coatings Market (Antimicrobial Powder Coatings and Surface Modifications & Coatings) for Indoor Air Quality, Medical/Healthcare, Mold Remediation, Textiles, Construction, Food and Other Applications: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022”. According to the report, the global anti-microbial coatings market accounted for USD 2.74 Billion in 2016 and is expected to reach USD 5.30 Billion by 2022, growing at a CAGR of around 11.7% between 2017 and 2022. The global anti-microbial coatings market is expected to witness significant growth over the forecast period on account of the increasing demand from the healthcare sector. Anti-microbial coatings are used to prevent the growth of microorganisms on the surface. It either destroys the microorganism or prevents its growth. The stringent regulations on the healthcare sector to use anti-microbial coatings are expected to be a major driver for the anti-microbial coatings market within the forecast period. Demand from high-end commercial and residential construction projects is also expected to aid the growth of the anti-microbial coatings market in the coming years. However, the quality regulations and health issues connected to the use of silver are expected to restrain the growth of anti-microbial coatings market within the forecast period. Technological advancements in order to improve efficiency and quality are expected to open new avenues of opportunities in the coming years. Browse through 23 Market Tables and 28 Figures spread through 167 Pages and in-depth TOC on “Global Anti-Microbial Coatings Market: By Type, Application, Size, Share, Trends, Analysis, Segment and Forecast 2016 – 2022”. Among the products, surface modification & coatings segment accounted for the largest market share in 2016 and is expected to grow at a significant rate. These are continuously being developed for certain surfaces to combat the presence of E. Coli and other bacteria. The anti-microbial powder coatings segment is expected to witness significant growth and this can be attributed to its applications in medical care, sanitation, steel furniture industry and domestic appliances. Indoor air quality was studied as the most dominant application segment in 2016 accounting for the largest share of the global anti-microbial coatings market. Initiatives are being taken by the regulatory bodies in order to educate the people about indoor air quality is expected to drive the demand for anti-microbial coatings for indoor air quality improvement within the forecast period. Medical/Healthcare segment accounted for the second largest market share of anti-microbial coatings in 2016 and is expected to grow in light of stringent regulations mandating the use of anti-microbial coatings on medical devices, equipment etc. Mole remediation segment is also expected to witness significant growth owing to the regulations to prevent the use of VOCs. Browse the full "Anti-Microbial Coatings Market (Antimicrobial Powder Coatings and Surface Modifications & Coatings) for Indoor Air Quality, Medical/Healthcare, Mold Remediation, Textiles, Construction, Food and Other Applications: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2016 - 2022" report at https://www.zionmarketresearch.com/report/anti-microbial-coatings-market North America accounted for the largest share of anti-microbial coatings market across the globe. North America is also expected to be the fastest-growing region for anti-microbial coatings market within the forecast period. Stringent regulations on the healthcare industry to adopt anti-microbial coatings are expected to be one of the major drivers for the market in this region. Improving living standards coupled with increased spending on healthcare have also contributed positively towards the growth of anti-microbial coatings market in North America. Europe anti-microbial coatings market is expected to witness significant gains within the forecast period owing to the stringent regulations mandating the use of anti-microbial coatings. The growth of the food industry in the region and other end-use industries is also expected to aid the growth of anti-microbial coatings market in Europe. Rising consumer awareness and applications such as indoor air quality are also spurring the growth of anti-microbial coatings market in the region. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/anti-microbial-coatings-market Asia Pacific is expected to register significant growth within the forecast period for anti-microbial coatings market. This can be attributed to the increasing demand from countries like China and India. The large population and rising construction industry in the region are expected to be the major drivers for anti-microbial coatings market in Asia-Pacific. The growing medical tourism in India is also expected to augment the demand from the healthcare sector. In addition, the rapidly growing food industry in the region is also expected to contribute positively towards the growth of Asia Pacific anti-microbial coatings market. Latin America is expected to witness moderate growth within the forecast period. The demand for anti-microbial coatings from the healthcare sector is expected to be the major driver for the market in Latin America. Rising health awareness is also expected to boost the growth of anti-microbial coatings market in the future. The Middle East and Africa is expected to witness sluggish growth for anti-microbial coatings market within the forecast period. The rising construction and infrastructure redevelopment activities in the region are expected to drive the demand for anti-microbial coatings in the region. The key players operating in the global anti-microbial coatings market are Microban International Ltd., Cupron Inc., Specialty Coatings Company Inc., AK Coatings Inc., HaloSource Inc., Dow Microbial Control, AcryMed Inc., Alistagen Corporation, AEGIS Environments, Sciessent LLC, BBJ Environmental Technologies Inc., EnviroCare Corporation, Fosters Products Corporation, Fiberlock Technologies Inc., Sports Coatings, Lonza Group Ltd., Semprus Biosciences Corporation, Troy Corporation and Sureshield Coatings Company. For more inquiry contact our sales team @ sales@zionmarketresearch.com This report segments the global anti-microbial coatings market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.


BASEL, Switzerland, CAMBRIDGE, Mass., BERKELEY, Calif., and DUBLIN, Ireland, Feb. 15, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), Caribou Biosciences, Inc., and ERS Genomics Limited provide an update on the Patent Trial & Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office (“USPTO”) decision on the motions filed by the University of California, the University of Vienna and Dr. Emmanuelle Charpentier (collectively, “UC”), on one hand, and the Broad Institute, Harvard University and the Massachusetts Institute of Technology (collectively, “Broad”), on the other, in the interference proceeding relating to CRISPR/Cas9 genome editing technology (“CRISPR/Cas9 Technology”). The PTAB discontinued the current interference finding that the claim sets presented by the two parties were considered “patentably distinct” from each other because UC’s current claims are broader in scope in that they are not restricted to use in eukaryotic cells, whereas Broad’s claims are all limited to use in eukaryotic cells. As a result of the decision, UC’s broader case, which was previously considered allowable but for the interference, is now released from the interference and may be prosecuted to potential issuance by UC, while a new interference can be sought with respect to eukaryote claims, currently pending in a separate UC patent application once they are deemed allowable. Alternatively, UC could appeal the current decision, which is currently under consideration. In parallel cases, the United Kingdom’s Intellectual Property Office (UK IPO) granted patents to foundational CRISPR/Cas9 genome editing technology in any non-cellular or cellular setting (including in human cells) to UC. The prosecution and enforcement of UC’s foundational intellectual property covering CRISPR/Cas9 Technology, such as this patent application, is governed by a global cross-consent and invention management agreement between the co-owners of the intellectual property – the Regents of the University of California, Emmanuelle Charpentier, and the University of Vienna – as well as their key licensees and sublicensees – CRISPR Therapeutics, ERS Genomics, Caribou Biosciences, and Intellia Therapeutics. The written decisions and associated documents relating to U.S. patent interference 106,048 are publicly available at https://acts.uspto.gov/ifiling/PublicView.jsp. Outside the United States, a UC application directed broadly to the single-guide CRISPR/Cas9 genome editing system (i.e. not limited by cellular or non-cellular setting) was examined by the United Kingdom’s Intellectual Property Office and, despite multiple evidentiary “observations” filed by third parties including the Broad, was granted as UK Patent No. 2518764. A second UK patent application, which is directed to chimeric CRISPR/Cas9 systems, was also the subject of third-party observations, and was granted as a patent on February 7, 2017 (UK Patent No. 2537000). Corresponding applications are being prosecuted in the European Patent Office and in other regional and national offices covering approximately 80 jurisdictions worldwide. Granted patents can be subject to proceedings challenging their grant, validity or scope. Almost all jurisdictions worldwide are “first-to-file” systems, which recognize the first patent applicant(s) as the legal inventor(s) and do not permit the filer of a later patent application to antedate the earlier filings of others. In the case of the CRISPR-Cas9 Technology, UC filed its first priority application on May 25, 2012, and Broad filed more than six months later on December 12, 2012. In the United States, with respect to patent applications filed prior to March 2013, a subsequent filer could claim to have invented before an earlier filer by filing a declaration in the USPTO, which is what the Broad did and led to the interference proceeding discussed herein. Broad’s related European patents have been opposed by numerous parties on procedural as well as substantive grounds, and are now the subject of proceedings challenging their validity and issuance at the Opposition Division of the European Patent Office. About CRISPR Therapeutics CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com. About Intellia Therapeutics Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets. About Caribou Biosciences, Inc. Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. The Company was founded by pioneers of CRISPR/Cas9 biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou’s tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. For more information, visit www.cariboubio.com and follow the Company @CaribouBio. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc. About ERS Genomics ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com. CRISPR Forward-Looking Statements Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the therapeutic value, development, and commercial potential of CRISPR/Cas-9 gene editing technologies and therapies and the intellectual property protection of our technology and therapies. You are cautioned that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties regarding the intellectual property protection for our technology and intellectual property belonging to third parties; uncertainties inherent in the initiation and completion of preclinical studies for the Company’s product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; expectations for regulatory approvals to conduct trials or to market products; and those risks and uncertainties described in Item 1A under the heading “Risk Factors” in the company’s most recent quarterly report on Form 10-Q, and in any other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The information contained in this press release is provided by the company as of the date hereof, and, except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking information contained in this press release. Intellia’s Forward-Looking Statements This press release contains “forward-looking statements” of Intellia within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include, but are not limited to, statements regarding Intellia’s ability to advance CRISPR/Cas9 into therapeutic products for severe and life-threatening diseases and its CRISPR/Cas9 intellectual property portfolio, and statements regarding the intellectual property position and strategy of Intellia’s licensors. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to Intellia’s ability to protect and maintain its intellectual property position, risks related to the ability of Intellia’s licensors to protect and maintain their intellectual property position, the risk that any one or more of Intellia’s product candidates will not be successfully developed and commercialized, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or development of Intellia’s product candidates, the risk that the results of previously conducted studies involving similar product candidates will not be repeated or observed in ongoing or future studies involving current product candidates, and the risk that Intellia’s collaborations with Novartis or Regeneron will not continue or will not be successful. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia Therapeutics undertakes no duty to update this information unless required by law. Disclaimer Regarding Third Party Websites The announcing companies are providing the above reference to the USPTO’s website as a third-party source of additional factual information relating to U.S. patent interference 106,048, and none of the announcing companies adopt any information contained or found in such reference. Any information in this press release accessible through such reference is as of the date of the release, and the announcing companies undertake no duty to update this information unless required by law.


LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces its post-earnings coverage on Becton, Dickinson and Co. (NYSE: BDX) ("BD"). The Company reported its first quarter fiscal 2017 financial results for the fourth quarter and fiscal on February 01, 2017. The medical technology firm surpassed top- and bottom-line expectation and raised its earnings outlook. Register with us now for your free membership at: One of Becton, Dickinson and Co.'s competitors within the Medical Instruments & Supplies space, The Cooper Companies, Inc. (NYSE: COO), announced on February 01, 2017, that it will release its Q1 2017 financial results on Thursday, March 02, 2017, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. AWS will be initiating a research report on Cooper Cos. a few days following its earnings release. Today, AWS is promoting its earnings coverage on BDX; touching on COO. Get our free coverage by signing up to: For the first fiscal quarter ended December 31, 2016, BD reported quarterly revenues of $2.922 billion, down 2.1% from the prior-year same period revenues, due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, the reported quarter revenues grew 6.1%. BD's revenue figures surpassed analysts' consensus of $2.85 billion. On a performance basis, BD's gross profit margin improved by 190 basis points compared to the year ago same quarter at 54.3%. This growth was driven by continuous improvement initiatives, cost synergies, and favorable mix which include the positive impact of divestitures. On an operating margin basis, the Company delivered an approximately 250 basis points of margin expansion to 23.8%, as it continues to drive cost synergies. In addition, margin expansion was positively impacted by the divestiture of the respiratory solutions business. For Q1 FY17, BD's diluted earnings per share were $2.58 compared to $1.06 in the prior-year comparable period. This represents an increase of 143.4% and is primarily due to a litigation reserve reversal following a favorable appellate antitrust ruling. The Company's adjusted diluted earnings per share were $2.33 in the reported quarter compared to $1.96 in the prior-year same period. This represents an increase in adjusted diluted earnings per share of 18.9%, or 19.4% on a currency-neutral basis. The earning numbers comfortably surpassed Wall Street's expectations of $2.12 per share. During Q1 FY17, in the BD's Medical segment, worldwide revenues totaled $1.964 billion down 4.4% from Q1 FY16 due to the divestiture of the Respiratory Solutions business. On a comparable, currency-neutral basis, revenues increased 7.5%. Performance in the Pharmaceutical Systems and Medication Management Solutions units was positively impacted, in part, by the timing of customer orders and capital placements, respectively, which occurred in Q1 FY17, earlier than the Company initially anticipated. In the BD Life Sciences segment, worldwide revenues for Q1 FY17 were $958 million, an increase of 2.7% over the prior-year comparable period, or an increase of 3.2% on a currency-neutral basis. The segment's revenue growth reflects strong performance in the Diagnostic Systems and Preanalytical Systems units. For Q1 FY17, BD's revenue in the US was $1.63 billion, a decrease of 3.6% from the prior-year same period due to the aforementioned divestiture. On a comparable basis, US revenues increased 5.5%. Within BD's Medical segment, growth was driven by strong performance in the Medication Management Solutions and Diabetes Care units. Growth in BD's Life Sciences segment was driven by solid growth in the Diagnostics Systems unit, and favorable timing of orders in Advanced Bioprocessing in the Biosciences unit. For Q1 FY17, BD's revenues outside of the US of $1.292 billion were about flat when compared with the prior year corresponding period due to the aforementioned divestiture. On a comparable, currency-neutral basis, revenues outside of the US increased 6.8%. For the international region within BD's Medical segment, growth was driven by capital installations in the Medication Management Solutions unit, and strength in the Pharmaceutical Systems unit, which was aided in part by the aforementioned timing of customer orders. Growth in BD's Life Sciences segment reflects sales of safety-engineered products, and strength in Latin America and Asia/Pacific in the Diagnostic Systems unit, including a favorable comparison to the prior-year's same period in China. BD expects FY17 revenues to decrease 3.5% to 4.0%, down compared to the previously issued guidance of a decrease of 3.0% to 3.5% due to the incrementally negative estimated impact from foreign currency. The Company continues to estimate that revenues for FY17 will increase 4.5% to 5.0% on a comparable, currency-neutral basis. The Company now expects FY17 diluted earnings per share to be between $7.90 and $8.00, which represents growth of approximately 76.0% to 78.0%. On a currency-neutral basis, the Company is raising FY17 adjusted diluted earnings per share to $9.70 to $9.80, which represents growth of 13.0% to 14.0% including an estimated 1.5% of dilution related to the Respiratory Solutions divestiture. This is an increase from previously issued guidance of $9.62 to $9.72, which represented approximately 12.0% to 13.0 % growth. On February 15, 2017, Becton, Dickinson and Co.'s share price finished the trading session at $180.09, slightly advancing 0.74%. A total volume of 855.05 thousand shares exchanged hands. The stock has advanced 3.85% and 27.05% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 8.78%. The stock is trading at a PE ratio of 29.93 and has a dividend yield of 1.62%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces its post-earnings coverage on Becton, Dickinson and Co. (NYSE: BDX) ("BD"). The Company reported its first quarter fiscal 2017 financial results for the fourth quarter and fiscal on February 01, 2017. The medical technology firm surpassed top- and bottom-line expectation and raised its earnings outlook. Register with us now for your free membership at: One of Becton, Dickinson and Co.'s competitors within the Medical Instruments & Supplies space, The Cooper Companies, Inc. (NYSE: COO), announced on February 01, 2017, that it will release its Q1 2017 financial results on Thursday, March 02, 2017, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. AWS will be initiating a research report on Cooper Cos. a few days following its earnings release. Today, AWS is promoting its earnings coverage on BDX; touching on COO. Get our free coverage by signing up to: For the first fiscal quarter ended December 31, 2016, BD reported quarterly revenues of $2.922 billion, down 2.1% from the prior-year same period revenues, due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, the reported quarter revenues grew 6.1%. BD's revenue figures surpassed analysts' consensus of $2.85 billion. On a performance basis, BD's gross profit margin improved by 190 basis points compared to the year ago same quarter at 54.3%. This growth was driven by continuous improvement initiatives, cost synergies, and favorable mix which include the positive impact of divestitures. On an operating margin basis, the Company delivered an approximately 250 basis points of margin expansion to 23.8%, as it continues to drive cost synergies. In addition, margin expansion was positively impacted by the divestiture of the respiratory solutions business. For Q1 FY17, BD's diluted earnings per share were $2.58 compared to $1.06 in the prior-year comparable period. This represents an increase of 143.4% and is primarily due to a litigation reserve reversal following a favorable appellate antitrust ruling. The Company's adjusted diluted earnings per share were $2.33 in the reported quarter compared to $1.96 in the prior-year same period. This represents an increase in adjusted diluted earnings per share of 18.9%, or 19.4% on a currency-neutral basis. The earning numbers comfortably surpassed Wall Street's expectations of $2.12 per share. During Q1 FY17, in the BD's Medical segment, worldwide revenues totaled $1.964 billion down 4.4% from Q1 FY16 due to the divestiture of the Respiratory Solutions business. On a comparable, currency-neutral basis, revenues increased 7.5%. Performance in the Pharmaceutical Systems and Medication Management Solutions units was positively impacted, in part, by the timing of customer orders and capital placements, respectively, which occurred in Q1 FY17, earlier than the Company initially anticipated. In the BD Life Sciences segment, worldwide revenues for Q1 FY17 were $958 million, an increase of 2.7% over the prior-year comparable period, or an increase of 3.2% on a currency-neutral basis. The segment's revenue growth reflects strong performance in the Diagnostic Systems and Preanalytical Systems units. For Q1 FY17, BD's revenue in the US was $1.63 billion, a decrease of 3.6% from the prior-year same period due to the aforementioned divestiture. On a comparable basis, US revenues increased 5.5%. Within BD's Medical segment, growth was driven by strong performance in the Medication Management Solutions and Diabetes Care units. Growth in BD's Life Sciences segment was driven by solid growth in the Diagnostics Systems unit, and favorable timing of orders in Advanced Bioprocessing in the Biosciences unit. For Q1 FY17, BD's revenues outside of the US of $1.292 billion were about flat when compared with the prior year corresponding period due to the aforementioned divestiture. On a comparable, currency-neutral basis, revenues outside of the US increased 6.8%. For the international region within BD's Medical segment, growth was driven by capital installations in the Medication Management Solutions unit, and strength in the Pharmaceutical Systems unit, which was aided in part by the aforementioned timing of customer orders. Growth in BD's Life Sciences segment reflects sales of safety-engineered products, and strength in Latin America and Asia/Pacific in the Diagnostic Systems unit, including a favorable comparison to the prior-year's same period in China. BD expects FY17 revenues to decrease 3.5% to 4.0%, down compared to the previously issued guidance of a decrease of 3.0% to 3.5% due to the incrementally negative estimated impact from foreign currency. The Company continues to estimate that revenues for FY17 will increase 4.5% to 5.0% on a comparable, currency-neutral basis. The Company now expects FY17 diluted earnings per share to be between $7.90 and $8.00, which represents growth of approximately 76.0% to 78.0%. On a currency-neutral basis, the Company is raising FY17 adjusted diluted earnings per share to $9.70 to $9.80, which represents growth of 13.0% to 14.0% including an estimated 1.5% of dilution related to the Respiratory Solutions divestiture. This is an increase from previously issued guidance of $9.62 to $9.72, which represented approximately 12.0% to 13.0 % growth. On February 15, 2017, Becton, Dickinson and Co.'s share price finished the trading session at $180.09, slightly advancing 0.74%. A total volume of 855.05 thousand shares exchanged hands. The stock has advanced 3.85% and 27.05% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 8.78%. The stock is trading at a PE ratio of 29.93 and has a dividend yield of 1.62%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SAN FRANCISCO, Feb. 27, 2017 /PRNewswire/ -- Fluxion Biosciences announced today that Genetracer Biotech of Santander, Spain has been appointed as a Certified Service Provider for Fluxion's IsoFlux CTC Liquid Biopsy System. The IsoFlux system will be used in Genetracer Biotech's novel...


News Article | March 1, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proclara Biosciences, a biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that Franz Hefti, Ph.D., president and chief executive officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 1:30 p.m. ET in Boston. Proclara Biosciences is a biotechnology company advancing product candidates developed based on proprietary GAIM technology, which is capable of simultaneously targeting multiple toxic misfolded proteins. The broad applicability of the Proclara technology enables the company to target multiple protein misfolding diseases, including neurodegenerative diseases and several rare systemic amyloidoses. The lead GAIM drug candidate, NPT088, is in clinical development for the treatment of Alzheimer’s disease. For more information, please visit proclarabio.com.

Loading Biosciences collaborators
Loading Biosciences collaborators